A failure of practice, or a failure of evidence?
Drug treatment of rheumatoid arthritis (RA) has evolved significantly in recent decades, owing to increasing evidence supporting early intervention with disease-modifying therapies and the advent of novel biological therapies that specifically target the immunological and cellular mediators of disease.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-134.
- 2. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33: 2398-2408.
- 3. Royal Australian College of General Practitioners. Clinical guideline for the diagnosis and management of early rheumatoid arthritis. Melbourne: RACGP, 2009.
- 4. Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis 2009; 68: 1081-1082.
- 5. Siegel J. Comparative effectiveness of treatments for rheumatoid arthritis. Ann Intern Med 2008; 148: 162-163.
- 6. Zink A, Askling J, Dixon WG, et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68: 1240-1246.
- 7. Kalden JR, Antoni C, Alvaro-Gracia JM, et al. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol 2005; 32: 1620-1631.
- 8. Benhamou M, Rincheval N, Roy C, et al. The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol 2009; 36: 934-942.
- 9. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005; 53: 241-248.
- 10. Grol R. Has guideline development gone astray? Yes. BMJ 2010; 340: c306.
- 11. Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-1465.
- 12. Boers M. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? Ann Intern Med 2009; 151: 668-669.
- 13. Australian Government Department of Health and Ageing. The national strategy for quality use of medicines. Plain English edition. Canberra: Commonwealth of Australia, 2002. http://www.health.gov.au/internet/main/publishing.nsf/content/nmp-pdf-natstrateng-cnt.htm
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.